{"ticker": {"uuid": "8bde399a-c5bb-4592-bb6b-ac3d129b9feb", "symbol": "BMRN", "name": "Biomarin Pharmaceutical Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE83dU1rYndJc3lPUE84Y29qdVhZSFZkMHRKLUdPZXp0SVJMZDdFekNxYlROZm9TT1lnLWNJR3czb1liNzFwcFY3Rkx3WGdtb1cyMEdJTndmb0x0X1FnMmRjYlc3SjdPM0UteXhHVw?oc=5", "source_name": "TipRanks", "published_at": "2026-07-21T18:48:27+00:00", "published_display": "21 Jul 2026 18:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops", "summary": "BioMarin Pharmaceutical Inc. (BMRN) stock remains steady as the company demonstrates growth in its rare disease revenue while actively developing gene therapy assets. The biotech firm's strategy involves substantial R&D investments in gene therapy programs, particularly for hemop", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biomarin-stock-trades-steady-as-rare-disease-revenue-grows-and-gene/69821666", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:41:25", "published_display": "21 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN5187965 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027 bond (BMRN5187965 FINRA). It lists key metrics such as issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also include", "url": "https://www.tradingview.com/symbols/FINRA-BMRN5187965/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-20T11:11:22", "published_display": "20 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:17+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (BMRN) Volatility", "summary": "This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) volatility, identifying a neutral near-term sentiment with a mid-channel oscillation pattern. It highlights an exceptional short setup with a 25.3:1 risk-reward ratio and outlines three AI-generated trading strateg", "url": "https://news.stocktradersdaily.com/news_release/81/Trading_Systems_Reacting_to_BMRN_Volatility_071726125601_1784307361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T13:11:52", "published_display": "17 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons to Avoid BMRN and 1 Stock to Buy Instead", "summary": "BioMarin Pharmaceutical (BMRN) is not recommended due to its stagnant adjusted operating margin and mediocre return on invested capital over the last five years. Despite a reasonable forward P/E, its shaky fundamentals present too much downside risk. The article suggests investin", "url": "https://finance.yahoo.com/markets/stocks/articles/2-reasons-avoid-bmrn-1-154546992.html", "source_name": "Market source", "published_at": "2026-07-17T11:45:00", "published_display": "17 Jul 2026 11:45", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BMRN6299744 Bond Risk Profile", "summary": "This article provides a risk profile for the BioMarin Pharmaceutical Inc. 5.5% 15-FEB-2034 corporate bond, identified as BMRN6299744. It outlines key metrics for credit risk assessment, including security level and issuer rating. The offering also suggests access to exclusive ana", "url": "https://www.tradingview.com/symbols/FINRA-BMRN6299744/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-15T15:09:57", "published_display": "15 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN6299744 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the BioMarin Pharmaceutical Inc. bond, BMRN6299744, highlighting its key metrics. It includes information such as the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The bond is a", "url": "https://www.tradingview.com/symbols/FINRA-BMRN6299744/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-15T14:41:01", "published_display": "15 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "H.C. Wainwright has reiterated its Neutral stock rating and $50 price target for BioMarin Pharmaceutical Inc., despite the company trading above this target. BioMarin recently announced that the FDA accepted its supplemental New Drug Application for the full approval of VOXZOGO f", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-biomarin-stock-rating-at-neutral-93CH-4790633", "source_name": "Investing.com", "published_at": "2026-07-15T04:11:53", "published_display": "15 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts BioMarin application for full VOXZOGO approval By Investing.com", "summary": "The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO for children with achondroplasia, setting a target action date of February 28, 2027. This application is supported by extensive long-term safety and efficacy data, a", "url": "https://ng.investing.com/news/stock-market-news/fda-accepts-biomarin-application-for-full-voxzogo-approval-93CH-2597064", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T14:14:00", "published_display": "14 Jul 2026 14:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral By Investing.com", "summary": "H.C. Wainwright has reiterated a Neutral stock rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50.00 price target. This comes after the FDA accepted BioMarin's supplemental New Drug Application for VOXZOGO for full approval in children with achondroplasia, with a ta", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-biomarin-stock-rating-at-neutral-93CH-4532131?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-14T12:13:05", "published_display": "14 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms", "summary": "BioMarin Pharmaceutical Inc. (BMRN) filed an amendment to its acquisition report, detailing Amicus Therapeutics' 2025 financial results and pro forma financials for their merger. The amendment revealed Amicus' 2025 net product sales of $634.2 million and a net loss of $27.1 milli", "url": "https://www.stocktitan.net/sec-filings/BMRN/8-k-a-biomarin-pharmaceutical-inc-amends-material-event-report-df34a73965cb.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:05", "published_display": "13 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts BioMarin application for full VOXZOGO approval", "summary": "The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO (vosoritide), used for children with achondroplasia. The target action date is February 28, 2027. This application is supported by extensive long-term safety and eff", "url": "https://www.investing.com/news/company-news/fda-accepts-biomarin-application-for-full-voxzogo-approval-93CH-4788700", "source_name": "Investing.com", "published_at": "2026-07-13T14:41:01", "published_display": "13 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-says-fda-accepts-filing-133712759.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:37:12+00:00", "published_display": "13 Jul 2026 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia", "summary": "BioMarin has announced that the FDA accepted its supplemental New Drug Application (sNDA) for VOXZOGO, targeting full approval for achondroplasia by February 28, 2027. This application is supported by extensive long-term safety and efficacy data from three ongoing studies, demons", "url": "https://intellectia.ai/news/stock/biomarin-seeks-full-approval-for-voxzogo-in-achondroplasia", "source_name": "Intellectia AI", "published_at": "2026-07-13T14:10:05", "published_display": "13 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA starts full review of BioMarin\u2019s VOXZOGO for children with achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkNYRWJMMnRReklOdjk5YjNxb19iSG5EQVZBNjhGRFp3ZThBZElpLUlyX3RiUXhyZTZVNVE0ZHE0bV9Nc2JQalplZzNSX1JrZkpPMXJRb2pwTjBnRzRGVldiYTFMNVZLR3B5OGxRVXR6VWo4bDlfV3FkRWl4TUhtMlp0OUlEX01abTA2M19DYldDWWRaR0NBN2dkY3U2d1ZHbkc0ckRNQi1QVkoydGxTWW5rVHdsd0lQcDhOdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin seeks full approval for VOXZOGO", "summary": "BioMarin Pharmaceutical's supplemental application for full FDA approval of VOXZOGO, a therapy for achondroplasia, has been accepted. The FDA has set a target action date of February 28, 2027, to review the submission, which includes long-term safety and efficacy data from ongoin", "url": "https://grafa.com/en/news/united-states/biomarin-voxzogo-fda-full-approval-achondroplasia", "source_name": "grafa.com", "published_at": "2026-07-13T13:38:00", "published_display": "13 Jul 2026 13:38", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO\u00ae (vosoritide) for Children With Achondroplasia", "summary": "BioMarin Pharmaceutical Inc. announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for VOXZOGO\u00ae (vosoritide) for full approval in children with achondroplasia. The application is supported by extensive long-term safety and efficacy data, including ", "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-accepts-biomarins-supplemental-new-drug-application-for-full-approval-of-voxzogo-vosoritide-for-children-with-achondroplasia-302823072.html", "source_name": "PR Newswire", "published_at": "2026-07-13T13:05:06", "published_display": "13 Jul 2026 13:05", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Young people with PKU take the mic in BioMarin podcast series", "summary": "BioMarin Pharmaceutical is launching a new video podcast series and TikTok campaign called \"Why Do I Pheel This Way?\" to raise awareness for phenylketonuria (PKU). Hosted by two young individuals with PKU, Connor and Londyn, the series explores their daily experiences with the ra", "url": "https://www.fiercepharma.com/marketing/biomarin-amplifies-voices-teens-pku-podcast-series-tiktok-campaign", "source_name": "Fierce Pharma", "published_at": "2026-07-11T01:10:08", "published_display": "11 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?", "summary": "BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, influencing its institutional investor perception. Despite a 5.47% 7-day and 6.31% 30-day share price return, its 3-year total shareholder return is down 29.21%. The company is considered 31.3% underval", "url": "https://www.sahmcapital.com/news/content/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after-its-russell-index-additions-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-10T13:42:06", "published_display": "10 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Lowers BioMarin Pharmaceutical Price Target to $62 From $66, Maintains Sector Perform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-lowers-biomarin-pharmaceutical-114747420.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:47:47+00:00", "published_display": "07 Jul 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook Reveals 48.92% Potential Upside", "summary": "BioMarin Pharmaceutical Inc. (BMRN), a biotechnology company specializing in rare disease therapies, shows a potential upside of 48.92% according to analyst ratings. With a market cap of $11.4 billion and a strong product pipeline including VIMIZIM and VOXZOGO, the company mainta", "url": "https://www.directorstalkinterviews.com/biomarin-pharmaceutical-inc-bmrn-investor-outlook-reveals-48-92-potential-upside/4121255561", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN - Biomarin Pharmaceutical Inc Options", "summary": "This article provides comprehensive financial data for BioMarin Pharmaceutical Inc. (BMRN), including its last close price, market capitalization, income, sales, and various financial ratios. It also details insider ownership, institutional ownership, profitability margins, and s", "url": "https://finviz.com/stock?t=BMRN&p=d&ty=oc&r=ytd&ov=chain_strike&s=95", "source_name": "Finviz", "published_at": "2026-07-03T21:40:42", "published_display": "03 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN - Biomarin Pharmaceutical Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of BioMarin Pharmaceutical Inc. (BMRN), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers aspects from market capitalization and earnings per share to vola", "url": "https://finviz.com/stock?t=BMRN&ta=1&p=d&ty=ocv&b=2&r=m1&ov=chain_strike&s=80", "source_name": "Finviz", "published_at": "2026-07-02T17:13:00", "published_display": "02 Jul 2026 17:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Index Additions And New VOXZOGO Data Change The Bull Case For BioMarin Pharmaceutical (BMRN)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued?", "summary": "BioMarin Pharmaceutical (BMRN) is under analysis after presenting new VOXZOGO and BMN 333 data at ENDO 2026 and releasing mixed quarterly results with updated guidance. The stock shows short-term momentum but is still down over a three-year period. Despite trading at a discount t", "url": "https://www.sahmcapital.com/news/content/biomarin-pharmaceutical-bmrn-highlights-endo-2026-progress-is-the-stock-undervalued-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-28T21:40:52", "published_display": "28 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. \u2013 NASDAQ:BMRN", "summary": "This article focuses on the enterprise value to revenue forward metric for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It appears to be a stub or a section of a larger financial analysis provided by TradingView, indicating a specific financial valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:13:01", "published_display": "26 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh", "summary": "This page provides an overview of Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:B1MR34) on TradingView. It offers access to actuals and estimates for financial data, including income statements, balance sheets, cash flow, and va", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-B1MR34/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:04", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN)", "summary": "This article provides an overview of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for revenue, earnings per share, net income, and EBITDA, and states the co", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:42", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioMarin Pharmaceutical Inc. \u2013 NASDAQ:BMRN", "summary": "This article displays the forward price-to-sales ratio for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It presents a specific financial metric for the company as listed on the Nasdaq Stock Market. The content is sparse, mainly serving as a data point within a larger financial in", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:41", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing", "summary": "Quantitative analysis suggests that Biomarin Pharmaceutical Inc. (BMRN) is exhibiting a mid-channel oscillation pattern, with strong near-term sentiment but a neutral mid and long-term outlook. The report identifies an exceptional 28.2:1 risk-reward setup targeting an 8.1% gain v", "url": "https://news.stocktradersdaily.com/news_release/1/How_Biomarin_Pharmaceutical_Inc._BMRN_Affects_Rotational_Strategy_Timing_062526042401_1782375841.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T04:24:00", "published_display": "25 Jun 2026 04:24", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment", "summary": "BioMarin (BMRN) presented positive Phase 2 extension study data for VOXZOGO (vosoritide) in children with hypochondroplasia, showing sustained improvements in growth parameters over three years. The company plans to submit a supplemental NDA to the FDA in Q3 2026. Additionally, B", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-bmrn-presents-positive-phase-185523530.html", "source_name": "Market source", "published_at": "2026-06-23T19:55:00", "published_display": "23 Jun 2026 19:55", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Most Promising Stocks with Highest Upside Potential", "summary": "This article highlights BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of the most promising stocks with high upside potential, noting its average upside potential of 55.42%. The company recently presented positive clinical data for its treatments for skeletal dysplasias, inc", "url": "https://www.insidermonkey.com/blog/10-most-promising-stocks-with-highest-upside-potential-1785156/3", "source_name": "Insider Monkey", "published_at": "2026-06-22T19:10:09", "published_display": "22 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOTVZBN0VZYzh2ODRqUlJmMzc2ZWYyTndqZjVRRk5vVDdjLVlxOEl2MDVENnBCTjIwNEl4aDBFVld0bFdYTGZNZVNzWmc0dFFrcnhGNV9TQWVOTDN1OEhmcXpsRW5ybHdnUGI4OG5vQTBMUUFIZWNYaTJDS0xmM0dyODZ3dlMzS3FjcE1WNTJNT042NTZqaURmQ2tCdEdDTDAteGtNbW9DTUpQNlFWV3NnM0dZZmZSQXVTVjYzTTYtdlFXeEo4Y0p3T3luWm5kUTRp?oc=5", "source_name": "ChartMill", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSlk0ZS05NFFGMWRTT19iZ3ExMjdFc0NrdUx6RUdnRWxtSXVSb1hpUkFpUVdkN0xEMVdSTS1qaWJNNTJEZ3RheE8xbDJyYWlEN0pKdHI5bzJHRWF1NWxhQVVwZmMycl8wYktzemxEamJhT2pFUUZWd2JHUzJqQ1l0NDExeWtIemYyVVdNUnBBbC1oTS16dDVUV3lrNzZXSkhPSGN4S19iZUZDNFU?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical stock (US09061G1013): higher 2026 sales outlook puts margins in the spotligh", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcWEzOEZUT2VvUDFzaS1URUM3SnhfNjcwakljQlNYZWtwSFExbmVyeEN6WmR3ZHZpU0tGbUNpd1hOTmtkWkJ0cXBDYjFNbWk3YXBoYU5yemk3VkFOdm1GZFgyT1pObjFRbFgtZlc5M3R5RUtsS1ZtMTFxOUliQUpFWUFwUFA3OTBRQVh3VEQ0QktGNGRzZ0piTE9uWDlZSnFJOHRUREpMRkNrVTRneVhjcHZFZnhINkpnUlMtWC1vWWFpWnpDTkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Its Multi\u2011Year Share Price Slide", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Margin Compression Challenges Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQkRNY0FoR3I2eDNqcEsteFVWNVk3TXl0elZmZXh5VGJ2T1g4d2tGX3ZERWs3VmdMazJtd0w0eXJTY0hsUGdCd1QzWnJHM09QNGdWbkpMd0d4UHJMNEZORDVZbW55ZXpKb0p4UEhjYlRmRXRvVlp5T3ZLYjBFd0xRTGpHang4RzBmVHJrRl9oek14MS03VWNwNmxUQjByMEZUM2txMWxSUXU0d0h2RnFEYzRDbjZva2Y3ZldLa3B2UFM5S21Z?oc=5", "source_name": "ChartMill", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQenJ0SlI0Qi1FWUlBa2ZIdm5ZN0piTkpwS1p6VWlTeE5aVGdRMHJnRTUtdzh2ZXhkNWhEdUtJMUxDS2oyOFZQeXJVT1RSVU9sRWhjaWJBVmxKUnZ4cm85ZS05WnNXZDYxVVNuSWJNM1RucVZxUkFiXzRSZWNCaDJQZk56LVhteGpBNDZYdXpLS043amZkcG5nRjZoUEw3Qk9xU0xMTHN2VzdqamV1SU10cUJtc3N5NWNISi1mem9fYTQxX0NTMlpKdW01dFdpRHJvWDRtUzNhU1U1N3JqUHZENzhYZkdnMlBmeHVsNGdMa29icmF6UnlRQnVXX1haY3N2?oc=5", "source_name": "TradingView", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin lines up $2B loan, $800M facility for Amicus deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNR0lOX3FISzVBMkxIcUtZNldKNFFrUHNnVFhrSnZFTEdjM2VGMGl0aU0wSFlObU1HaDhkeG5SOE9TRC1wczhnejV4NkhLZklxQVItbGU1aEEwVWh0NGt5QjcweFF2M2ZjNVRtR3VERHVfNjdGM1hDdUh2ZXVFZkViWnVhSlYxVVZTcWVnRzA4Y1ZRaDgyU3Z6WDExS2tPbnl2czBnbHRVLV9HajZKRU5MXzZBNlpjNWFvRWp1Vw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE83dU1rYndJc3lPUE84Y29qdVhZSFZkMHRKLUdPZXp0SVJMZDdFekNxYlROZm9TT1lnLWNJR3czb1liNzFwcFY3Rkx3WGdtb1cyMEdJTndmb0x0X1FnMmRjYlc3SjdPM0UteXhHVw?oc=5", "source_name": "TipRanks", "published_at": "2026-07-21T18:48:27+00:00", "published_display": "21 Jul 2026 18:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops", "summary": "BioMarin Pharmaceutical Inc. (BMRN) stock remains steady as the company demonstrates growth in its rare disease revenue while actively developing gene therapy assets. The biotech firm's strategy involves substantial R&D investments in gene therapy programs, particularly for hemop", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/biomarin-stock-trades-steady-as-rare-disease-revenue-grows-and-gene/69821666", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-21T11:41:25", "published_display": "21 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN5187965 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027 bond (BMRN5187965 FINRA). It lists key metrics such as issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also include", "url": "https://www.tradingview.com/symbols/FINRA-BMRN5187965/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-20T11:11:22", "published_display": "20 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T21:46:17+00:00", "published_display": "17 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (BMRN) Volatility", "summary": "This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) volatility, identifying a neutral near-term sentiment with a mid-channel oscillation pattern. It highlights an exceptional short setup with a 25.3:1 risk-reward ratio and outlines three AI-generated trading strateg", "url": "https://news.stocktradersdaily.com/news_release/81/Trading_Systems_Reacting_to_BMRN_Volatility_071726125601_1784307361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T13:11:52", "published_display": "17 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons to Avoid BMRN and 1 Stock to Buy Instead", "summary": "BioMarin Pharmaceutical (BMRN) is not recommended due to its stagnant adjusted operating margin and mediocre return on invested capital over the last five years. Despite a reasonable forward P/E, its shaky fundamentals present too much downside risk. The article suggests investin", "url": "https://finance.yahoo.com/markets/stocks/articles/2-reasons-avoid-bmrn-1-154546992.html", "source_name": "Market source", "published_at": "2026-07-17T11:45:00", "published_display": "17 Jul 2026 11:45", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN6299744 Bond Risk Profile", "summary": "This article provides a risk profile for the BioMarin Pharmaceutical Inc. 5.5% 15-FEB-2034 corporate bond, identified as BMRN6299744. It outlines key metrics for credit risk assessment, including security level and issuer rating. The offering also suggests access to exclusive ana", "url": "https://www.tradingview.com/symbols/FINRA-BMRN6299744/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-15T15:09:57", "published_display": "15 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN6299744 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the BioMarin Pharmaceutical Inc. bond, BMRN6299744, highlighting its key metrics. It includes information such as the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The bond is a", "url": "https://www.tradingview.com/symbols/FINRA-BMRN6299744/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-15T14:41:01", "published_display": "15 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral", "summary": "H.C. Wainwright has reiterated its Neutral stock rating and $50 price target for BioMarin Pharmaceutical Inc., despite the company trading above this target. BioMarin recently announced that the FDA accepted its supplemental New Drug Application for the full approval of VOXZOGO f", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-biomarin-stock-rating-at-neutral-93CH-4790633", "source_name": "Investing.com", "published_at": "2026-07-15T04:11:53", "published_display": "15 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts BioMarin application for full VOXZOGO approval By Investing.com", "summary": "The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO for children with achondroplasia, setting a target action date of February 28, 2027. This application is supported by extensive long-term safety and efficacy data, a", "url": "https://ng.investing.com/news/stock-market-news/fda-accepts-biomarin-application-for-full-voxzogo-approval-93CH-2597064", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T14:14:00", "published_display": "14 Jul 2026 14:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates BioMarin stock rating at Neutral By Investing.com", "summary": "H.C. Wainwright has reiterated a Neutral stock rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $50.00 price target. This comes after the FDA accepted BioMarin's supplemental New Drug Application for VOXZOGO for full approval in children with achondroplasia, with a ta", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-biomarin-stock-rating-at-neutral-93CH-4532131?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-14T12:13:05", "published_display": "14 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZzlFZXljSDNLSjZPTklhMFRRNjg3a0RvT2VVZEJlekdQYk12dklrSE5QV3dvUkc4OG1ialNhNjNnNzJGWnY4RzRxMjJJcmxGX19EcTZ3eDV3S1JkRkJhNkludERTZGZpR1FSVnJXdXJNbndBeXQ3a0VjcG1ydmIxV293QmlYY0N5VnQxVV96bGppZVRLMGk4djNXSnJEXzhLQ28xT1RDTm1kMGc?oc=5", "source_name": "Market source", "published_at": "2026-07-13T22:16:14+00:00", "published_display": "13 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms", "summary": "BioMarin Pharmaceutical Inc. (BMRN) filed an amendment to its acquisition report, detailing Amicus Therapeutics' 2025 financial results and pro forma financials for their merger. The amendment revealed Amicus' 2025 net product sales of $634.2 million and a net loss of $27.1 milli", "url": "https://www.stocktitan.net/sec-filings/BMRN/8-k-a-biomarin-pharmaceutical-inc-amends-material-event-report-df34a73965cb.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:10:05", "published_display": "13 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts BioMarin application for full VOXZOGO approval", "summary": "The FDA has accepted BioMarin Pharmaceutical Inc.'s supplemental New Drug Application for full approval of VOXZOGO (vosoritide), used for children with achondroplasia. The target action date is February 28, 2027. This application is supported by extensive long-term safety and eff", "url": "https://www.investing.com/news/company-news/fda-accepts-biomarin-application-for-full-voxzogo-approval-93CH-4788700", "source_name": "Investing.com", "published_at": "2026-07-13T14:41:01", "published_display": "13 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-says-fda-accepts-filing-133712759.html", "source_name": "MT Newswires", "published_at": "2026-07-13T13:37:12+00:00", "published_display": "13 Jul 2026 13:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia", "summary": "BioMarin has announced that the FDA accepted its supplemental New Drug Application (sNDA) for VOXZOGO, targeting full approval for achondroplasia by February 28, 2027. This application is supported by extensive long-term safety and efficacy data from three ongoing studies, demons", "url": "https://intellectia.ai/news/stock/biomarin-seeks-full-approval-for-voxzogo-in-achondroplasia", "source_name": "Intellectia AI", "published_at": "2026-07-13T14:10:05", "published_display": "13 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA starts full review of BioMarin\u2019s VOXZOGO for children with achondroplasia", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNkNYRWJMMnRReklOdjk5YjNxb19iSG5EQVZBNjhGRFp3ZThBZElpLUlyX3RiUXhyZTZVNVE0ZHE0bV9Nc2JQalplZzNSX1JrZkpPMXJRb2pwTjBnRzRGVldiYTFMNVZLR3B5OGxRVXR6VWo4bDlfV3FkRWl4TUhtMlp0OUlEX01abTA2M19DYldDWWRaR0NBN2dkY3U2d1ZHbkc0ckRNQi1QVkoydGxTWW5rVHdsd0lQcDhOdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T13:05:00+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin seeks full approval for VOXZOGO", "summary": "BioMarin Pharmaceutical's supplemental application for full FDA approval of VOXZOGO, a therapy for achondroplasia, has been accepted. The FDA has set a target action date of February 28, 2027, to review the submission, which includes long-term safety and efficacy data from ongoin", "url": "https://grafa.com/en/news/united-states/biomarin-voxzogo-fda-full-approval-achondroplasia", "source_name": "grafa.com", "published_at": "2026-07-13T13:38:00", "published_display": "13 Jul 2026 13:38", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO\u00ae (vosoritide) for Children With Achondroplasia", "summary": "BioMarin Pharmaceutical Inc. announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for VOXZOGO\u00ae (vosoritide) for full approval in children with achondroplasia. The application is supported by extensive long-term safety and efficacy data, including ", "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-accepts-biomarins-supplemental-new-drug-application-for-full-approval-of-voxzogo-vosoritide-for-children-with-achondroplasia-302823072.html", "source_name": "PR Newswire", "published_at": "2026-07-13T13:05:06", "published_display": "13 Jul 2026 13:05", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Young people with PKU take the mic in BioMarin podcast series", "summary": "BioMarin Pharmaceutical is launching a new video podcast series and TikTok campaign called \"Why Do I Pheel This Way?\" to raise awareness for phenylketonuria (PKU). Hosted by two young individuals with PKU, Connor and Londyn, the series explores their daily experiences with the ra", "url": "https://www.fiercepharma.com/marketing/biomarin-amplifies-voices-teens-pku-podcast-series-tiktok-campaign", "source_name": "Fierce Pharma", "published_at": "2026-07-11T01:10:08", "published_display": "11 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?", "summary": "BioMarin Pharmaceutical (BMRN) was recently added to several Russell indexes, influencing its institutional investor perception. Despite a 5.47% 7-day and 6.31% 30-day share price return, its 3-year total shareholder return is down 29.21%. The company is considered 31.3% underval", "url": "https://www.sahmcapital.com/news/content/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after-its-russell-index-additions-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-10T13:42:06", "published_display": "10 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Lowers BioMarin Pharmaceutical Price Target to $62 From $66, Maintains Sector Perform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-lowers-biomarin-pharmaceutical-114747420.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:47:47+00:00", "published_display": "07 Jul 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook Reveals 48.92% Potential Upside", "summary": "BioMarin Pharmaceutical Inc. (BMRN), a biotechnology company specializing in rare disease therapies, shows a potential upside of 48.92% according to analyst ratings. With a market cap of $11.4 billion and a strong product pipeline including VIMIZIM and VOXZOGO, the company mainta", "url": "https://www.directorstalkinterviews.com/biomarin-pharmaceutical-inc-bmrn-investor-outlook-reveals-48-92-potential-upside/4121255561", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNjRHVUp0bWQ3WUdBN2Q4VGJhVU9sZWdteVJhcElTeHF2am9TZjE4WnFYZFI4RHhSSjdrTDdmckJ3TjU2WTZUMFdJSTZOdFJRVlFkdkctMXZBWkg4OVJZUkFqZ0F4WEJFNFVMODNLTTdpUVA1cGNSY0x3LTZYS0ZpYWpBYUkyY1EtTEcyNl9iUnUzYnJIdnVzaFFkbUFwbmU2MDJEUjc4ZU1kWjJxLXdKdTQ0d2xlWHIyS3hnRVhyRm43elZjUVNQQkVDQnE5S1ZoQ1B3bWlaeVpmbTVtN1E?oc=5", "source_name": "ChartMill", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN - Biomarin Pharmaceutical Inc Options", "summary": "This article provides comprehensive financial data for BioMarin Pharmaceutical Inc. (BMRN), including its last close price, market capitalization, income, sales, and various financial ratios. It also details insider ownership, institutional ownership, profitability margins, and s", "url": "https://finviz.com/stock?t=BMRN&p=d&ty=oc&r=ytd&ov=chain_strike&s=95", "source_name": "Finviz", "published_at": "2026-07-03T21:40:42", "published_display": "03 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMRN - Biomarin Pharmaceutical Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of BioMarin Pharmaceutical Inc. (BMRN), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers aspects from market capitalization and earnings per share to vola", "url": "https://finviz.com/stock?t=BMRN&ta=1&p=d&ty=ocv&b=2&r=m1&ov=chain_strike&s=80", "source_name": "Finviz", "published_at": "2026-07-02T17:13:00", "published_display": "02 Jul 2026 17:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Index Additions And New VOXZOGO Data Change The Bull Case For BioMarin Pharmaceutical (BMRN)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued?", "summary": "BioMarin Pharmaceutical (BMRN) is under analysis after presenting new VOXZOGO and BMN 333 data at ENDO 2026 and releasing mixed quarterly results with updated guidance. The stock shows short-term momentum but is still down over a three-year period. Despite trading at a discount t", "url": "https://www.sahmcapital.com/news/content/biomarin-pharmaceutical-bmrn-highlights-endo-2026-progress-is-the-stock-undervalued-2026-06-28", "source_name": "Sahm", "published_at": "2026-06-28T21:40:52", "published_display": "28 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. \u2013 NASDAQ:BMRN", "summary": "This article focuses on the enterprise value to revenue forward metric for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It appears to be a stub or a section of a larger financial analysis provided by TradingView, indicating a specific financial valuation ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:13:01", "published_display": "26 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh", "summary": "This page provides an overview of Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:B1MR34) on TradingView. It offers access to actuals and estimates for financial data, including income statements, balance sheets, cash flow, and va", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-B1MR34/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:11:04", "published_display": "26 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN)", "summary": "This article provides an overview of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for revenue, earnings per share, net income, and EBITDA, and states the co", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:42", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioMarin Pharmaceutical Inc. \u2013 NASDAQ:BMRN", "summary": "This article displays the forward price-to-sales ratio for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It presents a specific financial metric for the company as listed on the Nasdaq Stock Market. The content is sparse, mainly serving as a data point within a larger financial in", "url": "https://www.tradingview.com/symbols/NASDAQ-BMRN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:41", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWklvMjNjZnd5RXdSRDNYSFYwVkhOTkNGTXFhalg4SVVkWGV6NS1xQmg3OWlzMlI1Q25RR0xRdnhockQ1c1FzbUNWRl9DeE9yWHpMR3haTkxjLXRwUjk0dkktc1VlYmZTSVlwdzYxaFpQRjBQLUdNbklxRnBLTVIxNWdSeXpzYml6dXVLZUJrTFU0YXNMSC1HcHRRdE1VTTQ5RTJN?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing", "summary": "Quantitative analysis suggests that Biomarin Pharmaceutical Inc. (BMRN) is exhibiting a mid-channel oscillation pattern, with strong near-term sentiment but a neutral mid and long-term outlook. The report identifies an exceptional 28.2:1 risk-reward setup targeting an 8.1% gain v", "url": "https://news.stocktradersdaily.com/news_release/1/How_Biomarin_Pharmaceutical_Inc._BMRN_Affects_Rotational_Strategy_Timing_062526042401_1782375841.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T04:24:00", "published_display": "25 Jun 2026 04:24", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment", "summary": "BioMarin (BMRN) presented positive Phase 2 extension study data for VOXZOGO (vosoritide) in children with hypochondroplasia, showing sustained improvements in growth parameters over three years. The company plans to submit a supplemental NDA to the FDA in Q3 2026. Additionally, B", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-bmrn-presents-positive-phase-185523530.html", "source_name": "Market source", "published_at": "2026-06-23T19:55:00", "published_display": "23 Jun 2026 19:55", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Most Promising Stocks with Highest Upside Potential", "summary": "This article highlights BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of the most promising stocks with high upside potential, noting its average upside potential of 55.42%. The company recently presented positive clinical data for its treatments for skeletal dysplasias, inc", "url": "https://www.insidermonkey.com/blog/10-most-promising-stocks-with-highest-upside-potential-1785156/3", "source_name": "Insider Monkey", "published_at": "2026-06-22T19:10:09", "published_display": "22 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Announces New Three-Year VOXZOGO\u00ae (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxPMk9MNE9fWE52OFI2MFQ4ay1HZExONVlwM01QcUJQOW5JcXpwS1NlR0pCVE82QWpVcE45ZjZ5dHdEck9oWk9tbHplcjJQZFBuMlVRR1hWRklrNDJqUlJ0OFFfSlRXLWFoSmVVdGdTSXdkVldtNzFITkpCTjlITlcxMkJtdG5yQXJGRlBxUGtFem5RdG80cUstMmpaUjhxRW9Qb3RXTnU1a1RRRXpGWjM2NXpxT2hlYWlDVzJDdEZQN3FuRnMzeGhIekk1NmFySHV4eU9xRWtZVzdpbEVEQTlELTh1TjRhYUdMaWVLclVzWTlBR09WWEUycGpHWTNTX0hMeW1F?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOTVZBN0VZYzh2ODRqUlJmMzc2ZWYyTndqZjVRRk5vVDdjLVlxOEl2MDVENnBCTjIwNEl4aDBFVld0bFdYTGZNZVNzWmc0dFFrcnhGNV9TQWVOTDN1OEhmcXpsRW5ybHdnUGI4OG5vQTBMUUFIZWNYaTJDS0xmM0dyODZ3dlMzS3FjcE1WNTJNT042NTZqaURmQ2tCdEdDTDAteGtNbW9DTUpQNlFWV3NnM0dZZmZSQXVTVjYzTTYtdlFXeEo4Y0p3T3luWm5kUTRp?oc=5", "source_name": "ChartMill", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORlg3R29XNml0ZW16dzh3Q0xYSlItTU1qdDQ2X3VGUDNKTmNqUHJIQmFaQS00a0ZCNml2NFdMNHFwQTRMUWpYSnlad1puUDAySkxXZ3gwWWd3X2t3cjhYNl9LMndnVWtoWVc1c0hsSVdkUkoyTzd4TlZMbWxnTGV2a09fN2NmdXBkRTV0VFJDUGpZSFdTNUwtNlZwam5QeE84WFhWSUZWbmxOU0FrSXVz?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSlk0ZS05NFFGMWRTT19iZ3ExMjdFc0NrdUx6RUdnRWxtSXVSb1hpUkFpUVdkN0xEMVdSTS1qaWJNNTJEZ3RheE8xbDJyYWlEN0pKdHI5bzJHRWF1NWxhQVVwZmMycl8wYktzemxEamJhT2pFUUZWd2JHUzJqQ1l0NDExeWtIemYyVVdNUnBBbC1oTS16dDVUV3lrNzZXSkhPSGN4S19iZUZDNFU?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2WmJMbkM0MHowNVRzNU5sS240ckptbm52WlNR?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical stock (US09061G1013): higher 2026 sales outlook puts margins in the spotligh", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcWEzOEZUT2VvUDFzaS1URUM3SnhfNjcwakljQlNYZWtwSFExbmVyeEN6WmR3ZHZpU0tGbUNpd1hOTmtkWkJ0cXBDYjFNbWk3YXBoYU5yemk3VkFOdm1GZFgyT1pObjFRbFgtZlc5M3R5RUtsS1ZtMTFxOUliQUpFWUFwUFA3OTBRQVh3VEQ0QktGNGRzZ0piTE9uWDlZSnFJOHRUREpMRkNrVTRneVhjcHZFZnhINkpnUlMtWC1vWWFpWnpDTkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Its Multi\u2011Year Share Price Slide", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical (BMRN) Margin Compression Challenges Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports First Quarter 2026 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESDRjRTdDRWhYQXpSUWJHQUtUVFZkLUpXeVJjbTRIZHBUODNhMFM1YWdqNDVremtWblNManY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Completes Acquisition of Amicus Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdVlTT1VIM19nY2JWQVN0b1hZSEpRSHRlOWVTaUVkQ2pBeVpwSnZWZnlwcVIwR3VWTkFza2ZSUDF1ZW42NE9zRmk0MUtDWU1iM1RPWlBoanhLQ3RLUmJOeHhwN3ZxYjdQSTFjR3QzRWU2WHktdU85VkRYWmZtUmVheWdJYkItUGdZZTJOcDl0dERETXhsWlZQbThjaWxNVF9CdTZBbk94RDVlTlJ6bVE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNQkRNY0FoR3I2eDNqcEsteFVWNVk3TXl0elZmZXh5VGJ2T1g4d2tGX3ZERWs3VmdMazJtd0w0eXJTY0hsUGdCd1QzWnJHM09QNGdWbkpMd0d4UHJMNEZORDVZbW55ZXpKb0p4UEhjYlRmRXRvVlp5T3ZLYjBFd0xRTGpHang4RzBmVHJrRl9oek14MS03VWNwNmxUQjByMEZUM2txMWxSUXU0d0h2RnFEYzRDbjZva2Y3ZldLa3B2UFM5S21Z?oc=5", "source_name": "ChartMill", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQenJ0SlI0Qi1FWUlBa2ZIdm5ZN0piTkpwS1p6VWlTeE5aVGdRMHJnRTUtdzh2ZXhkNWhEdUtJMUxDS2oyOFZQeXJVT1RSVU9sRWhjaWJBVmxKUnZ4cm85ZS05WnNXZDYxVVNuSWJNM1RucVZxUkFiXzRSZWNCaDJQZk56LVhteGpBNDZYdXpLS043amZkcG5nRjZoUEw3Qk9xU0xMTHN2VzdqamV1SU10cUJtc3N5NWNISi1mem9fYTQxX0NTMlpKdW01dFdpRHJvWDRtUzNhU1U1N3JqUHZENzhYZkdnMlBmeHVsNGdMa29icmF6UnlRQnVXX1haY3N2?oc=5", "source_name": "TradingView", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNdFZ6TTl1TXh6Yk5hakNaUEpMS3lyVHdJR25hTVdPREdsSFQ5c1VldEpxTUp3bmc3dXBtU00teFVxdVpjS1QyXzJJNXFtZFgwMUlMRU1nblVzbkpnM0RGRGJuM1VTUHYwTHlyY01LZDRRSHRKNms5TzRQOURkcFB1d2F4b0FGSktxYlZWUEFDU1hIY1FqZlMzVVlMLVFteVdtSjlveGFQcjkyU0RQbEx2Vkd2clBKWmJmcFFYdlFiZFc2NW0tRllOcEtlTW5zbFZyZF9Cbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioMarin lines up $2B loan, $800M facility for Amicus deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNR0lOX3FISzVBMkxIcUtZNldKNFFrUHNnVFhrSnZFTEdjM2VGMGl0aU0wSFlObU1HaDhkeG5SOE9TRC1wczhnejV4NkhLZklxQVItbGU1aEEwVWh0NGt5QjcweFF2M2ZjNVRtR3VERHVfNjdGM1hDdUh2ZXVFZkViWnVhSlYxVVZTcWVnRzA4Y1ZRaDgyU3Z6WDExS2tPbnl2czBnbHRVLV9HajZKRU5MXzZBNlpjNWFvRWp1Vw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 63, "sentiment_summary": {"positive": 22, "negative": 5, "neutral": 36, "score": 57, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}], "positive_events": 22, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 59.59, "latest_week": "2026-07-17", "one_week_move": 0.8, "four_week_move": 9.0, "twelve_week_move": 12.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.858554, "market_dynamics_buy_signal": false, "relative_strength": -5.382614, "fair_value_gap": -15.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.8347, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.8% over one week, +9.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "PR Newswire", "count": 5}, {"label": "Stock Titan", "count": 3}, {"label": "ChartMill", "count": 3}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 22}, {"label": "Market update", "count": 22}, {"label": "Analyst action", "count": 8}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.8% over one week, +9.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides"}], "updated_at": "2026-07-22T08:40:29.091775+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}